Organism: Homo sapiens
Gene: 38481_at
Selected probe(set): 201528_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of 38481_at (201528_at) across 6674 perturbations tested by GENEVESTIGATOR:

Relative Expression (log2-ratio):4.9940987
Number of Samples:4 / 4

Experimental	B-CLL study 11 (rolipram)
	Peripheral blood mononuclear cells (PBMCs) obtained from chronic lymphocytic leukemia (CLL) patients and in vitro treated with rolipram (20 uM, cyclic nucleotide phosphodiesterase (PDE4) inhibitor) for 4 hours. PBMCs’ samples contained 90% CD19+ CD5+ B lineage CLL cells (B-CLL). Inclusion criteria: untreated CLL patients or at least 1 month after chemotherapy. Exclusion criteria: patients with active infections or other serious medical conditions or with white blood cell (WBC) counts of 15,000/l. ATC code:---
Control	rolipram study 4 (normal B-cell; 20uM)
	MACS purified resting B-cells from healthy donor peripheral blood treated with rolipram (20 uM, cyclic nucleotide phosphodiesterase (PDE4) inhibitor) for 4 hours. ATC code:---

Relative Expression (log2-ratio):4.4763126
Number of Samples:4 / 4

Experimental	B-CLL study 11 (DMSO)
	Peripheral blood mononuclear cells (PBMCs) obtained from chronic lymphocytic leukemia (CLL) patients and in vitro treated with vehicle (DMSO) for 4 hours. PBMCs’ samples contained 90% CD19+ CD5+ B lineage CLL cells (B-CLL). Inclusion criteria: untreated CLL patients or at least 1 month after chemotherapy. Exclusion criteria: patients with active infections or other serious medical conditions or with white blood cell (WBC) counts of 15,000/l.
Control	vehicle (DMSO) treated normal B-cell sample
	MACS purified resting B-cells from healthy donor peripheral blood treated with vehicle (DMSO) for 4 hours.

Relative Expression (log2-ratio):-3.2516165
Number of Samples:4 / 6

Experimental	F. tularensis study 1 (tularensis Schu S4)
	Peripheral blood monocytes infected with the Schu S4 isolate of Francisella tularensis (100 MOI) for 24 hours.
Control	uninfected peripheral blood monocyte sample
	Peripheral blood monocytes uninfected.

Relative Expression (log2-ratio):2.8003397
Number of Samples:2 / 2

Experimental	immune cell study 6 (PB; memory)
	Memory B-cells (CD20+/CD10-/CD27+) isolated from peripheral blood (PB). B-cells were isolated by negative selection, labeled with mAb specific for CD20, CD10, CD21, and CD27 and sorted for CD20+/CD10-/CD27+.
Control	immune cell study 6 (PB; CD21hi)
	Immature (transitional) B-cells (CD20+/CD10+/CD27-/CD21hi) isolated from peripheral blood (PB). B-cells were isolated by negative selection, labeled with mAb specific for CD20, CD10, CD21, and CD27 and sorted for CD20+/CD10+/CD27-/CD21hi.

Relative Expression (log2-ratio):2.7928019
Number of Samples:2 / 2

Experimental	immune cell study 6 (PB; memory)
	Memory B-cells (CD20+/CD10-/CD27+) isolated from peripheral blood (PB). B-cells were isolated by negative selection, labeled with mAb specific for CD20, CD10, CD21, and CD27 and sorted for CD20+/CD10-/CD27+.
Control	immune cell study 6 (PB; CD21lo)
	Immature (transitional) B-cells (CD20+/CD10+/CD27-/CD21lo) isolated from peripheral blood (PB) B-cells were isolated by negative selection, labeled with mAb specific for CD20, CD10, CD21, and CD27 and sorted for CD20+/CD10+/CD27-/CD21lo.

Relative Expression (log2-ratio):-2.6777172
Number of Samples:8 / 8

Experimental	PMA; ionomycine study 2
	CD4+ memory T cells derived from peripheral blood of healthy subjects were stimulated for 3 hours with phorbol 12-myristate 13-acetate (PMA, 10 ng/ml) and ionomycin (1 µg/ml). ATC code:---
Control	unstimulated CD4 memory T-cell sample
	Unstimulated CD4+ memory T cells derived from peripheral blood of healthy subjects.

Relative Expression (log2-ratio):-2.6424913
Number of Samples:4 / 2

Experimental	renal cell carcinoma study 6 (chromophobe type)
	Tumor tissue samples from the kidney of patients with chromophobe renal cell carcinoma (cRCC).
Control	normal kidney tissue (fetal)
	Normal fetal kidney tissue samples.

Relative Expression (log2-ratio):2.548049
Number of Samples:2 / 4

Experimental	glioma study 17 (glioblastoma; unsorted)
	Brain cells isolated from high grade glioblastoma (grade IV). Tumor tissue was dissociated using enzymatic treatment and all cells were used for RNA isolation.
Control	non-tumor cortical tissue
	Cortical tissue obtained from patients with epilepsy, but without any manifested brain cancer. The tissue was dissociated using enzymatic treatment, but all brain cell types were used for analyses.

Relative Expression (log2-ratio):2.519518
Number of Samples:2 / 4

Experimental	glioma study 17 ( small cell glioblastoma; unsorted)
	Brain cells isolated from high grade small cell glioblastoma (grade IV). Tumor tissue was dissociated using enzymatic treatment and all cells were used for RNA isolation. Patients were 56 ± 3 years old males.
Control	non-tumor cortical tissue
	Cortical tissue obtained from patients with epilepsy, but without any manifested brain cancer. The tissue was dissociated using enzymatic treatment, but all brain cell types were used for analyses.

Relative Expression (log2-ratio):2.51612
Number of Samples:3 / 3

Experimental	glioma study 17 (glioblastoma; A2B5+)
	Oligodendrocyte progenitor cells (OPC) isolated from high grade glioblastoma (grade IV). OPC were isolated using magnetic-activated cell sorting (MACS) with antibodies against A2B5 antigen. Patients were 66 ± 5 years old males.
Control	non-tumor oligodendrocyte progenitor cell sample (cortex)
	Oligodendrocyte progenitor cells (OPC) isolated from cortical tissue, which was obtained from patients with epilepsy, but without any manifested brain cancer. OPC were isolated using magnetic-activated cell sorting (MACS) with antibodies against A2B5 antigen.